PROCEED

Treatment tested

• Interferon beta-1a

  Interferon alpha/beta receptor agonist

Other measures (29)

Inclusion Criteria: * Male and female subjects between 18 to 65 years of age * Female subjects must be neither pregnant nor breast-feeding and must lack child-bearing potential as defined in the protocol * Subjects diagnosed with CIS or RMS according to the revised McDonald criteria (2010) * Treatment-naive subjects or subjects treated with Rebif® multi-dose injected by RebiSmart™ for no longer than 6 weeks prior to Baseline visit * Subjects that are able to self-inject with RebiSmart™ (in the opinion of the physician) * Subjects with Expanded Disability Status Scale (EDSS) score less than (\<) 6 (inclusive) at Baseline * Signed informed consent and subject data collection form Exclusion Criteria: * Subjects experiencing a relapse within 30 days before Baseline * Participation in other studies within 30 days before Baseline * Received any MS therapy within 6 months prior to study enrolment (for example, other disease-modifying drugs: immunomodulatory, immunosuppressive agents or combination therapy) with the exception of Rebif® multi-dose injected by RebiSmart™ * Any visual or physical impairment that precludes the subject from self-injecting the treatment using the RebiSmart™ * Pregnancy and breast-feeding * Serious or acute heart disease such as uncontrolled cardiac dysrhythmias, uncontrolled angina pectoris, cardiomyopathy, or uncontrolled congestive heart failure, as per investigator opinion * Current or past (within the last 2 years) history of alcohol or drug abuse * Have any contra-indications to treatment with interferon beta-1a according to Summary of Product Characteristics

This is a Phase 4, interventional, multicenter study of subcutaneous Rebif® (interferon beta-1a) using RebiSmart™ device to assess effectiveness and adherence of treatment in subjects with clinically isolated syndrome (CIS) or relapsing multiple sclerosis (RMS).